|Previous Section||Index||Home Page|
|Hammersmith Hospitals NHS Trust total||4,791||4,609||4,209||4,316||4,242||5,322||5,404||5,804||5,805||5,726||6,146|
|Medical and dental staff||818||743||737||781||524||548||751||812||913||911||953|
|Non-medical staff total||3,973||3,866||3,472||3,535||3,718||4,774||4,653||4,992||4,892||4,815||5,193|
|Professionally qualified clinical staff total||2,163||2,265||1,930||1,920||2,079||2,838||2,762||3,017||2,879||2,850||3,048|
|Qualified nursing, midwifery and health visiting staff||1,658||1,645||1,352||1,337||1,481||2,161||2,095||2,345||2,178||2,034||2,210|
|Qualified scientific, therapeutic and technical staff total||505||620||578||583||598||677||667||672||701||816||838|
|Qualified allied health professionals||243||229||205||199||218||222||208||213||213||254||265|
|Other qualified scientific, therapeutic and technical staff||262||391||373||384||380||455||459||459||488||562||573|
|Support to clinical staff total||n/a||956||983||1,074||1,057||1,382||1,306||1,380||1,343||1,325||1,471|
|Support to doctors and nurses||n/a||765||776||873||882||1,174||1,042||1,123||884||862||979|
|Support to ST&T||n/a||191||207||201||175||208||264||257||459||463||492|
|NHS infrastructure support total||n/a||644||555||537||577||552||574||583||658||626||658|
|Hotel, property and estates staff||n/a||163||147||136||122||118||98||94||123||96||94|
|Managers and senior managers||90||114||100||97||121||121||115||120||132||151||159|
|Other and unknown total||0||1||4||4||5||2||11||12||12||14||16|
Mr. Paterson: To ask the Secretary of State for Health whether the Department holds data from the process of licensing Herceptin for late stage breast cancer that could be made available to expedite the licensing of the drug for early stage breast cancer. 
Jane Kennedy: When the marketing authorisation holder, Roche, submits a licence variation application for the use of Herceptin in early stage breast cancer, new clinical data will be required to support this indication. The Medicines and Healthcare products Regulatory Agency already holds the quality, pre-clinical and clinical data which it assessed for Herceptin for the indication of late stage breast cancer and these will be available if required. However, it is very unlikely there will be a need to reassess previously submitted data.
Bill Wiggin: To ask the Secretary of State for Health what steps she is taking to ensure provision of free influenza vaccinations for people who qualify in areas where supplies of the vaccine have been exhausted. 
Caroline Flint: Having been alerted that some general practitioners may be facing a shortage of vaccine, the Department wrote to all primary care trust flu immunisation co-ordinators with details of how to order additional vaccine from our contingency stock, should extra be required by practices in their area. This vaccine has now been distributed to those affected practices. In addition to this, we have also secured an extra 800,000 doses of vaccine which will be delivered this month.
Ms Abbott: To ask the Secretary of State for Health what information the Department collects on the ethnicorigin of patients treated for mental ill-health in Hackney North and Stoke Newington. 
|Any other White background||160||140||300|
|White and Black Caribbean (Mixed)||20||30||50|
|White and Black African (Mixed)||20||10||30|
|White and Asian (Mixed)||0||10||10|
|Any other Mixed background||10||10||10|
|Indian (Asian or Asian British)||50||40||90|
|Pakistani (Asian or Asian British)||40||20||70|
|Bangladeshi (Asian or Asian British)||130||70||190|
|Any other Asian background||30||20||50|
|Caribbean (Black or Black British)||150||160||310|
|African (Black or Black British)||170||130||300|
|Any other Black background||140||80||220|
|Any other ethnic group||40||20||50|
Mr. Pelling: To ask the Secretary of State for Health whether the pilot use in Croydon of minibuses instead of ambulances to ferry inebriated patients to hospital has been considered for introduction in other parts of the country. 
Jane Kennedy: The Government is always interested in new initiatives to tackle alcohol harms. We are aware that London Ambulance Service is currently piloting the use of minibuses instead of ambulances to ferry patients involved in minor alcohol-related incidents to hospital. This trial will be reviewed in January and we will be interested to see the outcome of the evaluation.
Jane Kennedy: Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the yellow card scheme. Approximately 19,000 reports of suspected ADRs are sent to the MHRA/CHM through this scheme each year. It is not possible to estimate from the yellow card scheme the number of people who suffer adverse reactions to medicines since the scheme is associated with an unknown level of under-reporting.
It is important to note that the submission of a suspected ADR report does not necessarily mean that it was caused by the drug. Many factors have to be taken into account in assessing causal relationships, including temporal association, the possible contribution of concomitant medication and the underlying disease.
|Number of reports with a fatal outcome|
A study funded by the MHRA and published in the British Medical Journal on 2 July 2004, was conducted in two large hospitals in Merseyside in order to ascertain the current burden of ADRs in the national health service. The study found that of 18,820 patients aged over 16 years admitted to hospital over a six-month
19 Jan 2006 : Column 1527W
period, there were 1,225 admissions judged to be related to an ADR, giving a prevalence of 6.5 per cent. Of these 1,225, the ADR was judged to lead directly to the admission in 80 per cent. of cases. The median bed stay was eight days, accounting for 4 per cent. of the hospital bed capacity. The projected annual cost of such admissions to the NHS was £466 million.
|Next Section||Index||Home Page|